Angiopoietin and Adverse Outcomes in Cardiac Surgery

NCT05817929 | Recruiting

• 1 other identifier: PI2023_843_0015
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Conditions

Cardiac Surgery; Acute Kidney Injury

Keywords

angiopoietin; endothelial injury; MACCE

Outcome Measures

Primary Outcomes (2)

• Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event

  major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

  28 days

• correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event

  major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

  28 days

Secondary Outcomes (8)

• Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications

  28 days

• Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications

  28 days

• Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months

  3 months

• Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months

  3 months

• Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months

  6 months

Study Arms (1)

cardiac surgery

EXPERIMENTAL

Other: blood sample

Interventions

blood sample OTHER

5 ml blood sample will be withdrawn at the surgery start and at the surgery end

cardiac surgery

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• adult patient scheduled for cardiac surgery under cardiopulmonary bypass

You may not qualify if:

• patient less than 18 years old,
• redo surgery,
• urgent surgery,
• endocarditis,
• aortic root repair surgery
• aortic dissection
• heart beating surgery,
• heart transplantation

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens Picardie

Amiens, France

RECRUITING

MeSH Terms

Conditions

Acute Kidney Injury

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Osama ABOU ARAB, MD

CONTACT

03 22 08 78 36; abouarab.osama@chu-amiens.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2023
• First Posted: April 18, 2023
• Study Start: March 23, 2023
• Primary Completion: April 1, 2026
• Study Completion (Estimated): April 1, 2027
• Last Updated: May 25, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)